From molecules to medicines.
Explore our pipeline

Explore the groundbreaking therapies we’re developing to give patients better treatment options

Our pipeline
Partner up?
Get in contact

We are dedicated to developing a robust and sustainable pipeline of product candidates with the potential to revolutionize patient care and improve health outcomes.

With this in mind, we’re building a broad internal pipeline of product candidates focused on the treatment of endocrine and metabolic diseases.

Discovery
Lead optimization
IND-enabling studies
Phase 1
Phase 2
Development rights
CFTX-1554 | Peripheral Pain
Target: AT2R
Approach: Antagonist
Read more
CFTX-1554 | Peripheral Pain
Target: AT2R
Approach: Antagonist
Read more

CFTX-1554 is a novel inhibitor of the angiotensin II type 2 receptor (AT2R) in clinical development, representing a non-opioid approach to treating neuropathic pain

  • AT2R is a clinically precedented target
  • Licensed to Eli Lilly and Company
More about Lilly partnership
Phase 1

$630

million

Total amount Confo can receive in upfront and milestone payments from Lilly

$590

million

Total amount of additional milestones if Lilly proceeds with a second product candidate

Phase 1

$630

million

Total amount Confo can receive in upfront and milestone payments from Lilly

$590

million

Total amount of additional milestones if Lilly proceeds with a second product candidate

CFTX-1554 is a novel inhibitor of the angiotensin II type 2 receptor (AT2R) in clinical development, representing a non-opioid approach to treating neuropathic pain

  • AT2R is a clinically precedented target
  • Licensed to Eli Lilly and Company
More about Lilly partnership
CFTX-2034 | Post-Bariatric Hypoglycemia
Target: SSTR5
Approach: Agonist
Read more
CFTX-2034 | Post-Bariatric Hypoglycemia
Target: SSTR5
Approach: Agonist
Read more

CFTX-2034 is an antibody-based SSTR5 agonist designed for the treatment of Post-Bariatric Hypoglycemia (PBH) which is a serious metabolic condition that can develop after weight loss surgery.

More about CFTX-2034
IND-enabling studies

160,000 +

patients who are currently living with PBH in the US

IND-enabling studies

160,000 +

patients who are currently living with PBH in the US

CFTX-2034 is an antibody-based SSTR5 agonist designed for the treatment of Post-Bariatric Hypoglycemia (PBH) which is a serious metabolic condition that can develop after weight loss surgery.

More about CFTX-2034
Obesity
Target: GPR75
Approach: Antagonist
Obesity
Target: GPR75
Approach: Antagonist
Lead optimization
Lead optimization
Multiple Obesity Programs
Target: GLP1R, GIPR, Amylin R and GCGR
Approach: Agonist/Antagonist
Multiple Obesity Programs
Target: GLP1R, GIPR, Amylin R and GCGR
Approach: Agonist/Antagonist
Discovery
Discovery
Hypoparathyroidism
Target: PTHR1
Approach: Agonist
Hypoparathyroidism
Target: PTHR1
Approach: Agonist
Discovery
Discovery
Additional Programs
Target: Multiple
Approach: MultiGen® Platform
Additional Programs
Target: Multiple
Approach: MultiGen® Platform
Discovery
Discovery

What makes our pipeline special?

We have a unique way to tackle validated biology

Central to the development of impactful medicines is a foundation in solid, validated biology. We are focused on discovering and developing product candidates with clear biological mechanisms to address critical unmet medical needs of patients. Our proprietary technology enables us to uniquely tackle validated biology in a way that has never been done before.

 

Our technology
Paolo ai
Paolo ai
“Our pipeline demonstrates our pursuit of therapeutic breakthroughs. Each product candidate represents hope for patients” Paolo Vicini | Chief Development Officer
Rob scot hall way ai for launch
Rob ai 2
“Confo is at a pivotal stage in its growth, boasting an exciting pipeline of therapeutics targeting significant unmet needs in metabolic and endocrine diseases” Rob Scott | Independent Board Director
Joan ai final for launch
Joan ai final for launch
"We leverage our cutting-edge platform technology to accelerate the discovery and development of novel treatments in partnership with leading pharmaceutical companies.” Joan Vermeiren | Head of Development Project Management

Work with us to revolutionize GPCR-directed medicines

Whether you are looking to understand our science, partner, or build your career with us, Confo offers unique opportunities for you to help bring novel medicines to patients.

Partner with us

Explore partnership opportunities

Invest in us

Explore our investor consortium

Work with us

Join our team and shape the future